Toyama-shi, Japan
Toyama-shi, Japan

Time filter

Source Type

Kobayashi D.,Tohoku University | Kusama M.,Tohoku University | Onda M.,Daiichi Fine Chemical Co. | Nakahata N.,Tohoku University
Journal of Pharmacological Sciences | Year: 2011

It has been reported that pantothenic acid (vitamin B5) and panthenol, an alcohol derivative of pantothenic acid, have beneficial moisturizing effects on the skin. However, few studies have investigated the mechanism of action of pantothenic acid on skin tissues. We tried to clarify the role of pantothenic acid on skin function by using keratinocytes and fibroblasts. The depletion of pantothenic acid from the culture medium suppressed keratinocyte proliferation and promoted differentiation. Moreover, pantothenic acid depletion decreased the synthesis of keratinocyte growth factor and procollagen 4a2 in fibroblasts. These results suggest that pantothenic acid is essential for maintaining keratinocyte proliferation and differentiation. © The Japanese Pharmacological Society.


Rumberger J.A.,The Princeton Longevity Center | Napolitano J.,Independent Consultant | Azumano I.,Daiichi Fine Chemical Co. | Kamiya T.,Kyowa Hakko United States | Evans M.,KGK Synergize Inc.
Nutrition Research | Year: 2011

Safety and efficacy of a biologically active derivative of vitamin B 5 (pantethine) on total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) metabolism was studied in North American subjects at conventional low to moderate cardiovascular disease (CVD) risk. A total of 120 subjects initiated a therapeutic lifestyle change (TLC) diet 4 weeks before randomization (baseline) and maintained the diet throughout a 16-week study period; at baseline, subjects were randomized in a triple-blinded manner to either pantethine (600 mg/d, baseline to week 8, and 900 mg/d, weeks 9-16) or identically labeled, nonbiologically active placebo (n = 60 per group). We hypothesized that pantethine would lower TC and low-density lipoprotein in low-CVD-risk North American subjects in a similar manner as reported in high-CVD-risk subjects studied mainly in Italy and Japan. While sustaining a TLC diet and in comparison with placebo, pantethine demonstrated significant (P < .005) and sustained reductions (from baseline to week 16) in TC (6 mg/dL, 0.16 mmol/L, 3%), LDL-C (4 mg/dL, 0.10 mmol/L, 4%), and apolipoprotein B (4 mg/dL, 0.04 g/L, 5%). Our data suggest that pantethine supplementation for 16 weeks (600 mg/d for weeks 1-8 then 900 mg/d for weeks 9-16) is safe and significantly lowers TC and LDL-C over and above the effect of TLC diet alone. Although the absolute magnitude of these effects was small in these low- to moderate-risk North Americans (4-6 mg/dL), the results are noteworthy as prior studies have shown that, for each 1 mg/dL (0.026 mmol/L) reduction in LDL-C, there is a concomitant 1% reduction in overall future CVD risk. © 2011 Elsevier Inc.


Urano N.,Kyoto University | Kataoka M.,Kyoto University | Ishige T.,Kyoto University | Kita S.,Daiichi Fine Chemical Co. | And 2 more authors.
Applied Microbiology and Biotechnology | Year: 2011

NADP+-dependent aminoalcohol dehydrogenase (AADH) of Rhodococcus erythropolis MAK154 catalyzes the reduction of (S)-1-phenyl-1-keto-2- methylaminopropane ((S)-MAK) to d-pseudoephedrine, which is used as a pharmaceutical. AADH is suggested to participate in aminoalcohol or aminoketone metabolism in this organism because it is induced by the addition of several aminoalcohols, such as 1-amino-2-propanol. Genetic analysis of around the aadh gene showed that some open reading frames (ORFs) are involved in this metabolic pathway. Four of these ORFs might form a carboxysome-like polyhedral organelle, and others are predicted to encode aminotransferase, aldehyde dehydrogenase, phosphotransferase, and regulator protein. OrfE, a homologous ORF of the FadR subfamily of GntR transcriptional regulators, lies downstream from aadh. To investigate whether or not orfE plays a role in the regulation of aadh expression, the gene disruption mutant of R. erythropolis MAK154 was constructed. The ΔorfE strain showed higher AADH activity than wild-type strain. In addition, a transformed strain, which harbored multi-orfE, showed no AADH activity even in the induced condition with 1-amino-2-propanol. These results suggest that OrfE is a negative regulator that represses aadh expression in the absence of 1-amino-2-propanol. © 2010 Springer-Verlag.


Patent
Daiichi Fine Chemical Co. and Hokkaido System Science Co. | Date: 2011-09-29

The invention provides a nucleic-acid-transfecting composition which exhibits low cytotoxicity, which facilitates an effective nucleic acid transfection into a cell, and which improves expression of the nucleic acid in the cell. The composition for transfecting a nucleic acid into a cell, contains a di(C_(12-16 )alkyl)dimethylammonium halide and a phospholipid.


Patent
Daiichi Fine Chemical Co. | Date: 2012-07-18

A pantethine phosphate ester represented by the following formula (1) or formula (2) exhibits superior tyrosinase inhibitory effect and melanin production inhibitory effect.


Patent
Daiichi Fine Chemical Co. | Date: 2010-09-06

A pantethine phosphate ester represented by the following formula (1) or formula (2) exhibits superior tyrosinase inhibitory effect and melanin production inhibitory effect.


Trademark
Daiichi Fine Chemical Co. | Date: 2012-10-02

Dietary ingredients, namely, active chemical ingredients for use in the manufacture of dietary supplements or nutritional supplements.


Trademark
Daiichi Fine Chemical Co. | Date: 2012-10-02

Dietary ingredients, namely, active chemical ingredients for use in the manufacture of dietary supplements or nutritional supplements.


Patent
Daiichi Fine Chemical Co. | Date: 2011-04-20

A compound represented by the following general formula (I) or a salt thereof:^(1) represents a glycosyl group, a phosphate group, or a phosphate group bound to R^(2); R^(2) represents -CH_(2)OH, -CHO, -CH_(2)NH_(2), CH_(2)-amino acid residue, or -CH_(2)-OPO_(2)H; and R^(3) represents hydrogen atom, or -PO_(3)H_(2), and a composition for cosmetics, medicaments, foodstuffs, and/or feeds containing the aforementioned compound or a salt thereof.


Trademark
Daiichi Fine Chemical Co. | Date: 2012-08-21

Chemicals, namely, chemical additives for use in the manufacture of skin care and hair products; chemicals, namely, pyridoxine phosphate; chemical reagents other than for medical or veterinary purposes. Soaps and detergents; perfumery, fragrances and incenses, all other than perfumes used as cosmetics or toiletries; cosmetics and non-medicated toiletries; dentifrices. Pharmaceutical, veterinary and sanitary preparations, namely, antibiotics, pharmaceutical preparations for the treatment of infectious diseases, allergy medications, veterinary vaccines, flea powders, hand-sanitizing preparations, disinfectants for medical instruments; reagents for medical purposes.

Loading Daiichi Fine Chemical Co. collaborators
Loading Daiichi Fine Chemical Co. collaborators